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Combination therapy, however, is superior and better tolerated than IFN
alone also for patients with cirrhosis.
Recently pegylated (Peg) IFN and consensus IFN have been developed
offering higher sustained response rates than ordinary IFN. In particular Peg
IFN, which has a prolonged halflife and offers sustained serum IFN levels for
one week, has been promising. Peg IFN given once a week, in practice
induction dosing, offers a more rapid c1earence ofHCV RNA from serum.
Virological SR rates with Pcg IFN accordingly have been doubled as
compared to those achieved with recombinant IFN given t.i.w. Ongoing
studies and pilot studies indicates that Peg IFN in combination with ribavirin
will improve virological SR rates to more than 50% also for patients with
the unfavourable genotype 1.
IMoS121 Viral hepatitis B: New approaches to management
S. W. Schalm
Dept. ofHepatology & Castroetlterology, Erasmus University Hospital,
Rotterdam, Netherlands
Most carriers of HBsAg have no indication for antiviral therapy at present.
Current antiviral therapies are effective in inducing a sustained virological
response in a small proportion ofpatients in need. In view ofthis. other goals
of therapy, in particular that of a sustained biochemical response with
prolonged therapy are of interest.
For hepatitis B therapy with alpha interferon is available. Results are often
suboptimal due to - according to a recent Eurohep trial- a too short duration
of therapy in potentially responding patients. In HBeAg-negative chronic
hepatitis interferon therapy for 1 year or longer is associated with a lower
incidence ofrelapse than a six-month course and a higher sustained response
rate. In addition, there is now the option of lamivudine monotherapy that
results in suppression of serum HBV DNA, normalization of serum
transaminases (ALT) and improvement in inflammatory activity in the
liver biopsy in 60-70% ofpatients as long as therapy is continued. However,
the emergence of drug resistant viral strains is a particular problem both for
HBeAg-postive and negative chronic hepatitis B.
New anti-HBV nucleoside analogues arc undergoing clinical testing.
Famciclovir has shown minimal anti-HBV activity and interest in the
drug as monotherapy is now fading. Two other guanidine derivatives
drugs (Iobucavir and entecavir) have stronger virus-suppressive potential;
development of lobucavir has been stopped because of longterm carcino-
genicity. A competitive inhihitor of deoxyadenosine (adefovir) is active
against wildtype and lamivudine- resistant hepatitis B virus; its development
may be hampered by renal toxicity. Future effective therapy most likely will
include a (specific?) immunostimulant. Currently combination therapy of
interferon and lamivudine for a year is being tested for improved efficacy and
diminished incidence of resistance.
IMoS131 Elimination of hepatitis Bvirus infection through
vaccination: project. program. problems. prognosis
R. Steffen
Division ofEpidemiology and PrevelJlion of Communicable Diseases, Institute
for Social and PrevelJlive Medicine, University ofZurich, Zurich, Switzerland
Worldwide, hepatitis B virus (HBV) infection is responsible for over 1
million deaths each year and ranks 25th with respect to world wide burden of
disease. In 1992 the World Health Assembly of the WHO recommended
that hepatitis B vaccine be integrated into national immunization programs
in all countries by 1997. As of 1999, 110 countries have a national policy for
routine hepatitis B immunization, and 6 additional countries have a policy
fot immunizing groups at increased risk for HBV infection. All industria-
lized countries except few in Northwestern Europe and Japan routinely
immunize children with hepatitis B vaccine, as do many countries in the
developing world. In many less developed countries financial shortcomings
and weak immunization infrastructures have complicated the addition of
hepatitis B vaccine to their immunization schedules. Routine infant immu-
nization programs are still needed in sub-Saharan Africa, the Indian
subcontinent, and the Newly Independent States. In France, concerns
about possible vaccine side effects have resulted in decreased compliance
with the vaccination despite the fact that, epidemiologic studies have shown
no association between the vaccine and these side effects. With a vaccine
efficacy of about 95%, routine hepatitis B vaccination of all children would
mh<t:mtially reduce HBV-related morbidity and mortality worldwide.
Elimination is a potential target in the long-term only dul.' to thl.' long-
term sustainability of the human reservoir. It is questionable whether
eradication may be achieved.
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IMoS181 Travel medicine: New vaccines for old diseases
B. Genton
Swiss Tropuallnstitute, Basel; Medical University Politlinic, Lausanne,
Switzerland
With the enormous development of molecular biology and genetics, old
vaccines consisting of whole killed or live-attenuated organisms are pro-
gressively replaced by vaccines made of highly purified recombinant
proteins, synthetic peptidcs or even naked DNA. These compounds arc
definitely less reactogenic, but have the disadvantage of inducing lower
immune responses. To compensate for that, a lot of effort is being made to
develop new adjuvants, immunomodulators, carriers and delivery systems,
as well as appropriate mode of administtation and immunization schedules.
Several new vaccines fot travellers have been commercialised recently,
including for example the combined hepatitis A & B vaccine, a new
injectable typhoid vaccine and an oral cholera vaccine. A number of
others are cuttent!y in Phase III efficacy trials including vaccines against
travellers' diarrhoea, malaria and hepatitis E.
Although the tendency is to develop combined vaccines, the number of
injections and the cost becomes a real concern for both the travel medicine
practitioners and the clients. More precise risk-benefit and costeffectiveness
evaluations are needed in order to propose the right vaccinations for the right
trip. Also travellers must be remembered that vaccines are only an adjunct to
the overall health care. and not an alternative to preventive behaviour.
~om STDs resistance patterns and standard treatments
E. Nagy
Department ofClinical Microbiology, University of Szeged, Hungary
Travelling (particularly abroad) involves health risks as compared to the
hazards of everyday travel-free life. The risks include the acquisition of
infectious diseases not present in the home country (e.g. various tropical
diseases), gastroenteritis (the most frequent case) and sexually transmitted
diseases (STDs) Short-time migration often leads to increased sexual risk.-
taking with casual partners. Mobile prostitution has become an increasing
epidemiological factot for the spread of STDs, including high-level anti-
biotic-resistant pathogens.
Recent social-economic changes have resulted in dramatic increases in the
prevalence of syphilis in almost all eastern and central European countries
(e.g. the increase of syphilis in Russia in 1996 was 61 times as compared to
1989, up to 265 cases{l00 000 population). Because of the poot economic
situation, sensitive laboratory screening and diagnostic methods are used to
only a limited extent for the detection of C. trachomatis and N. gono"hoeae
infections. Following the emergence of penicillin, tetracyclin and spectino-
mycin-resistant N. gonorrhoeae in different parts of the world, CDC has
recommended that 3rd-generation cephalosporins and ftuoroquinolones be
used to treat patients with uncomplicated gonorrhoea. During recent years,
no expressed resistance to the 3rd-generation cephalosporins has been
observed, but a clinically significant increase of resistance to ciproftoxacin
has emerged. Typing methods help us to follow the spread of multiply
resistant N. gono"hoeae in both developed and undeveloped countries. New
effective treatment recommendations are needed for countries with different
epidemiological situations involving STDs.
IMoS21 I Diarrhoea in travellers - Prevention .. treatment
H. Pichler
4th Medical Department, Kaiser Franz Hosej Hospital, Vienna, Austria
20-50% ofthe approximately 20 million people who travel from temperate
industrialized countries to tropical countries each year acquire Traveller's
diarrhoea (TO). TD starts most ftequently between the 3rd and the 4th day
after arrival in a tropical area. The illness is generally selftimited, lasting 1-5
days. Bacterial enteric pathogens cause more than 75% of cases of TO. The
causative organisms vary considerably with location. In all areas enterotoxi-
genic E. coli (ETEC) is the most common isolate from persons with the
classic secretory traveller's diarrhoea syndrome ranging from approximately
SU% in Latin America to 15%, in Asia. Shigella, Salmonella and Campylo-
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bacter spp., classic pathogens ofinvasive dysenteric disease, are isolated in 1-
15% of cases. Vibrio species are most common in Asia. Less common
bacteria are Aeromonas hydrophila and Plesiomonas shigelloides. Parasitic
causes of TD include E. histolytica, G. lamblia and Cryptosporidium.
Viruses such as Rotavirus and Norwalk-like Virus have been isolated
from up to 12% of visitors to Latin America, Asia and Africa. The most
pragmatic approach to the prevention ofTD is the advice to "cook it, boil it,
peel it, or forget it". Prophylaxis with antinticrobials has been shown to be of
benefit in preventing TD with Trimethoprim-sulfamethoxazole and /luor-
oquinolones, but the routine use of these agents is generally not recom-
mended because of sideeffects of antibiotics and the development of
resistance. Antimicrobial prophylaxis can be discussed in patients with
inflammatory bowel disease, immunocompromised patients (HIV-infected
persons or transplant recipients) or patients for whom dehydration would be
dangerous. The mainstay of treatment is adaequate rehydration with oral
rehydration solution ev. supplemented with loperantide. Antimicrobials are
indicated in patients with severe abdominal pain, fever or dysentcry.
506 - Efflux pumps from basic science to the patients
IMoS23IAntibiotic efflux in dinically Important gram-
negative bacteria
Patrick Plesiat
Faculty of Medicine, Besan{on, France
Over the past decade, antibiotic efflux systems have been discovered in a
growing number ofbacterial pathogens. Extensive studies on Escherichia coli,
Pseudomonas aeruginosa and Neisseria gono"hoeae have led to the conclusion
that efflux pumps of the RND fantily play an essential role in the natural
resistance of these species to a vast array of inhibitors. For example, the
elevated intrinsic resistance ofP. aeruginosa to antibiotics mainly depends on
the expression of two poorly specific export systems (MexAB-OprM and
MexXY), the action of which is potentiated by the outer membrane
permeability barrier. In pathogens exhibiting more permeable outer mem-
branes, such as E. coli, efflux systems provide an efficient protection against
large or hydrophobic compounds (e.g. bile acids, defensins, and macrolides).
When overexpressed following mutations in regulatory genes, RND
pumps may produce clinically relevant resistance to a great many substrate
antibiotics (MICs x 2-16). Such efflux mutants have frequendy been
reported among clinical strains of P. aeruginosa. According to concordant
data, MexAB-OprM overproducers would account for 30 to 70% of the
carbenicillin resistance in hospital strains. The virulence status of the efflux
mutants however requires further investigations.
As demonstrated in E. coli and P. aeruginosa, efflux systems may have a
major impact on bacterial resistance when they are combined with other
mechanisms such as target alterations (DNA gyrase) or ,B-Iactamase produc-
tion. Furthermore, active export of antibiotics tends to increase the emer-
gence of highly resistant target mutants. For all these reasons, efBux
inhibitors would be invaluable drugs in the treatment of infections caused
by multidrug resistant strains.
IMoS241 Antibiotic efflux in dinically important Gram-positive
bacteria
Martin J. Gill
Division of Immunity & Infection, Medical School, University ofBirmingham,
Birmingham, United Kingdom
Efflux pumps are now well recognised in a number of Gram-positive
bacteria. The role of these pumps in normal physiology is unclear, but
their increased expression produces low-level antibiotic resistance Their role,
in combination with other resistance mechanisms, in producing clinical
significant resistance in is becoming increasingly important. Pumps which
appear to have a limited substrate range are macrolide pumps such as mefA
(Streptococcus pyogenes), mejE (Streptococcus pneumoniae) and mreA (Strepto-
coccus agalactiae) or the some oftet determinants (eg, tetK and tetL). The best
characterised pump in Staphylococcus aureus is NorA. Although Nora is
associated with quinolone resistance, it can use a wide range of substrates.
PmrA of Streptococcus pneumoniae is a pump similar to NorA. NorA and
PrnrA show structural and functional similarities to the efflux pumps Bmr
and Bit of Bacillus subtilis. However, it is likely that the regulation of Nora
and PmrA is different. Genome sequencing projects have indicated that
homologues to existing characterised pumps are found in a wide range of
bactena, Several pump. may exi.t in the .ame .train; homologues of Bmr,
Bit and EmrAB have been found in addition to Nora in a strain of
Staphylococcus aureus. Drugs which are not affected by efflux-mediated
resistance are being developed. Pump inhibitors are also being researched.
Efflux pumps can contribute to intrinsic antibiotic resistance. Their inactiva-
tion in different species is being developed as a sensitive tool for screening for
naturally occurring antimicrobial agents that would otherwise be effluxed
from the cell.
IMoS2S1 Efflux pumps in fungi. is it a real problem?
J. Bille
University Hospital, Lausanne, Switzerland
Mechanisms of resistance in yeasts and fungi are various and yet incomple-
tely worked out. Efflux pumps are implicated so far in acquired azole
resistance among yeasts, particularly Candida a/bicans, as well as some other
Candida species: C. glabrata, C. krusei, C. dublinimsis, C. tropicalis.
Evidence for their direct implication as mechanisms ofacquired resistance
in isogenie pairs or series ofclinical strains with increasing levels ofresistance
to fluconazole (F) are the following: i) increase efflux of azoles, as well as
other substrates of MDR transporters (rhodamine); ii) increase of mRNA
levels for MDR genes (CDR or MDR); iii) MDR gene over-expression in S.
cerevisiae confers resistance; iv) MDR gene deletion in C. albicans results in an
hypersusceptible strain.
So far, several efflux transporter genes have been characterised, belonging
either to the ATB Binding Cassette (CDR genes) or to the Major Facilitator
(BENr, FLU genes) transporters, conferring various degrees of cross-
resistance to azoles or other substrate•.
Clinical significance of efflux pumps mediated resistance in yeasts (parti-
cularly C. albicans) has been largely documented mainly in Aids patients
suffering from oropharyngeal candidiasis (OPC), particularly before
HAART. In other clinical settings, few cases have undoubtedly been
described where clinical resistance was correlated to acquired efBux mediated
F resistance after a short course of F. In a rat model ofendocarditis due to C.
albicans, inhibition of the efflux resistance mechanism by cyclosporin not
only restored the efficacy ofF to cure infection due to a F-resistant strain, but
also afforded significant better results than F alone when the strain was F-
susceptible.
Thus combining clinically administrable efflux pumps inhibitors to azoles
should be sought in order to improve the efficacy ofthis class ofantifungals.
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IMoS26IGlycopeptide resistance in Staphylococcus aureus
(GISA): From in vitro to in vivo
J. L. Mainardi, I. Podglajen
Service de Microbiologie Clinique, Hopital Broussais and Hopital Europlen
Georges Pompidou, Paris, France
The recent description of intermediate (homogeneous and heterogeneous)
glycopeptide-resistance of Staphylococcus aureus (GISA) has raised concern
about the importance of this potential public heath problem. However, the
emergence of GISA i. not a new phenomenon. Teicoplanin-resistant
mutants of S. aureus selected in vitro have been reported in severallabora-
tories since 1990. These studies have shown that teicoplanin was a more
efficient selective agent than vancomycin, even if more recently a highly
vancomycin-resistant mutant (MIC = 100 p.g/ml) of S. aureus has been
selected by Sieradzki et al. O. Bacteriol. 1997; 179: 2557-2566) by a step-wise
pressure procedure with vancomycin. The first in vivo emergence of
teicoplanin resistance, during therapy, of S. aureus has also been reported
in 1990 (Kaatzet al. J. Infect. Dis. 1990; 162: 103-108) and in several studies
since. The isolation of GISA strains, often in patients which have received
prolonged therapy with glycopeptides, and the possibility to select mutants
from hetero-GISA with further increased resistance to glycopeptides, both in
vitro and in vivo, underline the necessity to monitor carefully the serum levels
of glycopeptide during therapy.
IMoS27IGlycopeptide resistance in Staphylococcus aureus:
Mechanlsm(s) of resistance
H. Labischinski
Pharma Research Center, Bayer AG, Wuppertal, Germany
